Replies to post #48480 on Ayala Pharmaceuticals Inc (ADXS)

[Julius_Kelp]

The Oct 2017 corp presentation says combination data in 2018 for ADXS-PSA.

Metastatic Prostate Ph1/2 Combination with pembrolizumab
Part B Monotherapy Combination Therapy Data,

Prostate Cancer

? Significant opportunity; high unmet medical need and
sizeable patient population ? Phase 1/2 trial with Merck’s pembrolizumab ongoing
? Monotherapy activity promising
? Combination data in 2018

[Traderbx]

"The big disappointment I got from the article is seeing there may be no trial results at all this year. "

I listened to the entire ADXS conference call recording... there was an indirect reference that ADXS is trying to line up ADXS-PSA Combo trail is an ASCO candidate

[hovacre]

Well, I will be surprised if we don't get trial results this year, as that would be a crusher.

It's just that I don't expect we'll get much more from their most important studies, and I'm preparing myself to be surprised in the positive direction. I'd be happy to admit I was wrong.